文献速递帕金森病与运动障碍

帕金森病首次跌倒与复发性跌倒的预测

Prediction of First and Recurrent Falls in Parkinson's Disease
RSS 订阅 · Annals of Neurology · 2026-10-30

研究在PPMI队列开发并外部验证帕金森病次年跌倒的预测模型,并评估影像与体液生物标志物的增量价值。临床模型区分度中等,外部验证中效能有所下降;探索性生物标志物在开发队列有适度增量价值,外部验证中未体现。

要点

  • 首次跌倒模型含MDS-UPDRS第三部分、蒙特利尔认知评估和老年抑郁量表,外部验证AUROC为0.630。
  • 复发跌倒模型含Hoehn-Yahr分期、老年抑郁量表和符号数字模态测验,外部验证AUROC为0.641。
  • UPenn队列中首次跌倒风险从低危组7.1%升至高危组18.5%,复发跌倒率从22.2%升至65.0%。

核心结论

  • 临床指标或可以中等区分度识别帕金森病次年跌倒风险,但外部验证中效能有所下降。
  • 探索性生物标志物在开发队列提供适度增量价值,外部验证中未体现,且估计不精确。

研究设计与样本

  • 在帕金森病进展标志物计划(PPMI)中开发预测模型,并在宾夕法尼亚大学(UPenn)队列进行外部验证。
  • 首次跌倒模型在773个访视对中开发、589个访视对中验证;复发跌倒模型在302个访视对中开发、137个访视对中验证。

主要发现

  • 首次跌倒模型开发队列AUROC为0.704(95%CI 0.653–0.750),外部验证为0.630(95%CI 0.564–0.687)。
  • 复发跌倒模型开发队列AUROC为0.683(95%CI 0.623–0.753),外部验证为0.641(95%CI 0.538–0.732)。
  • UPenn队列中首次跌倒风险从低危组7.1%升至高危组18.5%,复发跌倒率从低危组22.2%升至高危组65.0%。

关键数值与推荐

  • 首次跌倒模型纳入MDS-UPDRS第三部分、蒙特利尔认知评估和老年抑郁量表(GDS)。
  • 复发跌倒模型纳入Hoehn-Yahr(H&Y)分期、老年抑郁量表和符号数字模态测验。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 外部验证中模型效能有所下降。
  • 外部验证中生物标志物增量价值的估计不精确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective To develop and externally validate prediction models for next-year falls in Parkinson's disease (PD), and to evaluate the incremental value of imaging and fluid biomarkers. Methods We developed models in Parkinson's Progression Markers Initiative (PPMI) to predict next-year falls with external validation in University of Pennsylvania (UPenn) cohorts. We evaluated incident falls among visits without current or prior falls and recurrent falls among visits with current falls. We calculated area under the receiver operating characteristic curve (AUROC), area under the precision-recall curve (AUPRC), and development-derived risk strata. Results The incident model, comprising Movement Disorder Society–Unified Parkinson's Disease Rating Scale Part III, Montreal Cognitive Assessment, and Geriatric Depression Scale (GDS), was developed in 773 visit-pairs and validated in 589 visit-pairs. AUROC was 0.704 (95% confidence interval [CI] = 0.653–0.750) in PPMI and 0.630 (95% CI = 0.564–0.687) in UPenn. Incident fall risk increased from 7.1 to 18.5% across low- to high-risk groups in UPenn. The recurrent model, comprising Hoehn and Yahr (H&Y), GDS, and Symbol Digit Modalities Test, was developed in 302 visit-pairs and validated in 137 visit-pairs. AUROC was 0.683 (95% CI = 0.623–0.753) in PPMI and 0.641 (95% CI = 0.538–0.732) in UPenn. Recurrent fall rates increased from 22.2 to 65.0% across low- to high-risk groups in UPenn. Exploratory biomarker augmentation modestly improved discrimination beyond clinical models in PPMI, but not in external validation, where estimates were imprecise. Interpretation Clinical measures may identify next-year fall risk in PD with moderate discrimination, although performance attenuated in external validation. Exploratory biomarkers provided modest incremental value in development but not in external validation. ANN NEUROL 2026

来源:Annals of Neurology,查看原文。版权归原作者所有。

引用

  1. Annals of Neurology:Prediction of First and Recurrent Falls in Parkinson's Disease

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。